# Patent

## Title
Attenuated gentically-engineered pseudorabies virus S-PRV-155 and uses

## Abstract

The invention provides methods and kits for determining the extent of interaction and/or inactivation between a cyclin/cyclin-dependent kinase inhibitor and the human papilomavirus E7 oncoprotein and thus for evaluating the proliferative state of a transformed cell. Methods for identifying compounds capable of inhibiting the interaction between a cyclin/cyclin-dependent kinase inhibitor and the human papilomavirus E7 oncoprotein, and for inhibiting growth of a human papillomavirus-associated carcinoma cell are also provided.

## Background
The present invention relates to the identification of compounds capable of inhibiting dysregulated cellular proliferation and/or differentiation caused by human papillomaviruses. The invention also relates to the field of characterizing proliferation of transformed cells, and more specifically, detection of proliferating cells transformed by human papillomaviruses.

Human papillomaviruses (HPVs) are small DNA viruses of the papovavirus family that infect human epithelial cells. About sixty genetically distinct strains of HPV have been identified to date, many of which appear to be responsible for different disease states. For example, "low-risk" HPVs, e.g., HPV-6 and HPV-11 cause benign hyperplasias such as genital warts, while "high-risk" HPVs, e.g., HPV-16 and HPV-18 can cause carcinomas such as cervical or penile carcinoma. On infection of a cell, the genomes of the HPVs are episomal, the low-risk HPV strains remaining so and the high-risk HPV integrating into the cellular genome in the course of pathogenesis. Two HPV encoded proteins, E6 and E7, are consistently expressed in the cancers and lead to transformation, or loss of control of growth, of infected cells. HPV E6 and E7 are thus commonly termed "oncoproteins".

The transforming functions of the papillomaviruses reflect their ability to interfere with control mechanisms that govern the normal program of cell growth and differentiation. Since the HPVs do not encode their own DNA replication machinery, they must exploit the host cell's replication apparatus in order to establish and maintain viral DNA replication in the infected tissue. Most of the skin cells that papillomaviruses infect have withdrawn from the cell replication cycle, having undergone an intricate program of terminal differentiation. Thus, in order to replicate viral DNA in such inactive cells, papillomaviruses subvert key regulatory mechanisms that govern cellular division and differentiation. For example, the HPV E6 oncoprotein interacts with the nuclear phosphoprotein p53 which is believed to act as a minor suppressor in its native state by functioning as a key mediator of DNA repair. The HPV E7 oncoprotein is known to interact with the "pocket proteins", a class of cellular proteins that include the retinoblastoma tumor suppressor protein pRB, p107, and p130.

The p53 and RB tumor suppressors are believed to act by imposing specific blocks to the progression of the cell cycle. If DNA damage occurs in a normal cell, wild type p53 levels increase. By virtue of its ability to bind to DNA in a sequence-specific manner, p53 stimulates expression of a number of genes, for example, the gene encoding a 21 kD protein variously known as p21, WAF1, SDI1, PIC1 and CIP1 (hereinafter referred to as p21.sup.CIP1). The nucleotide and amino acid sequences of p21.sup.CIP1 are set forth in SEQ ID NO:1 and SEQ ID NO:2. The p21.sup.CIP1 protein suppresses growth by inhibiting the activities of a class of protein kinases, the cyclin dependent kinases (cdks), which affect the temporal progression of the cell cycle. In their native state, the cdks form complexes with a regulatory subunit (a cyclin). A large number of cyclins have been identified, as have the specific cdks with which they associate. See, for example, PCT/US/00961 and T. Hunter et al., Cell 79, 573-582 (1994), incorporated herein by reference. When the cyclin/cdk complexes are inhibited by p21.sup.CIP1, cell division is blocked at an important checkpoint in the late G1 phase early in the cell replication cycle. When p21.sup.CIP1 does not inhibit the cyclin/cdk complexes, they stimulate cells to proceed through the cell cycle by phosphorylating and thus modulating the activity of the RB tumor suppressor as well as other regulatory proteins.

As set forth above, the HPV E7 oncoprotein also interacts with the RB tumor suppressor; however, the nature of the interaction differs from that of the cyclin/cdk complexes with RB. Hypophosphorylated RB suppresses transcription by complexing with the transcription factor E2F, and upon phosphorylation by the cyclin/cdk complexes, RB releases E2F, thus increasing transcription of genes needed for cellular replication. When HPV E7 binds to RB, E2F is also released.

Because of the prevalence of HPV infection, a need remains for additional diagnostic methods and therapeutic compounds. A need also exists for determining the potential for a pre-malignant high-risk HPV infection to progress to a malignant state.

The present inventors have for the first time discovered that the HPV E7 oncoprotein interacts with p21.sup.CIP1 and overcomes p21.sup.CIP1 inhibition of the kinase activity of cyclin/cdk complexes. In accordance with the invention, therefore, methods for identifying potential anti-carcinoma compounds, methods for inhibiting growth of HPV-infected cells, methods for determining the proliferative state of a transformed cell, and kits for diagnosing the proliferative state of HPV-infected cells are described.

In one embodiment, the invention provides a method of identifying a compound that inhibits the ability of human papillomavirus oncoprotein E7 to stimulate proliferation of human papillomavirus-infected cells, comprising the steps of: of aliquots; kinase inhibitor to at least two aliquots; respective aliquots

wherein a lesser kinase activity in the aliquot including the test compound compared to other aliquots is indicative of said test compound being a compound that inhibits the ability of human papillomavirus oncoprotein E7 to stimulate proliferation of the human papillomavirus-infected cells.

In another embodiment, the invention provides a method of inhibiting growth of a human papillomavirus-infected cell comprising administering to the cell a therapeutically effective mount of a compound that interferes with the ability of human papillomavirus oncoprotein E7 to interact with a cyclin-dependent kinase inhibitor.

In another embodiment, the invention provides a kit for diagnosing the proliferative state of a population of cells infected with a human papillomavirus, which comprises: accepting site on the dephosphorylated phosphoprotein, said compound being selected from the group consisting of a labeled phosphate and a labeled phosphate analog.

In another embodiment, the invention provides a kit for diagnosing the proliferative state of a population of transformed cells, which comprises: accepting site on the dephosphorylated phosphoprotein, said compound being selected from the group consisting of a labeled phosphate and a labeled phosphate analog.

In yet another embodiment, the invention provides a method of evaluating the proliferative state of a transformed cell which comprises: dividing said complexes into a plurality of aliquots; step a; the transformed cell; untransformed cell of step c, and dividing said complexes into a plurality of aliquots; d; and

wherein a proliferating transformed cell is characterized by a greater kinase activity in comparison to the kinase activity of the substantially homogeneic untransformed cell.

The foregoing and other objects of the invention, the various features thereof, as well as the invention itself, may be more fully understood from the following description, when read together with the accompanying drawings in which:

FIG. 1 sets forth a flow diagram of the invention as embodied in a method for identifying potential anti-carcinoma compounds.

FIG. 2 sets forth a flow diagram of the diagnostic method of the invention.

In accordance with the invention, an inhibitor of the kinase activity of cyclin/cyclin dependent kinase complexes and the HPV E7 oncoprotein are used in methods for identifying potential anti-carcinoma or anti-viral compounds and for diagnosing the proliferative states of transformed cells. As defined in the present invention, an inhibitor of the kinase activity of cyclin/cyclin dependent kinase complexes comprises any of a family of small cyclin-dependent kinase inhibitors known as CDIs which are capable of interacting with HPV E7. For example, the p21.sup.CIP1 protein having the amino acid sequence set forth in SEQ ID NO:1 and SEQ ID NO:2 or the p27.sup.KIP1 protein having the amino acid sequence set forth in SEQ ID NO:3 and SEQ ID NO:4 may be used in the methods of the invention.

The basic method of the invention may be performed as follows. Cyclin/cyclin dependent kinase complexes are isolated from mammalian cells, for example, by making an extract or lysate of the cells. Any mammalian cell may be used as a source of cyclin/cyclin dependent kinase complexes. For example, any of the mammalian cells described below in relation to recombinant expression of proteins may also be used as a source of cyclin/cyclin dependent kinase complexes. In addition, other cells may be used to prepare cyclin/cyclin dependent kinase complexes; for example, any transformed cell line may be used, as well as normal diploid cells, cell strains derived from in vitro culture of primary tissue, primary explants (especially from tumors), and the like, may act as a source for cyclin/cyclin dependent kinase complexes. The mammalian cells are grown in tissue culture using known methods; for example, the cells may be grown in monolayer culture or in liquid culture using a known nutrient solution supplemented with fetal calf serum and antibiotics. Preferably Dulbecco's Modified Essential Medium containing 10% fetal calf serum, streptomycin (50 .mu.g/ml) and penicillin (50 units/ml) is used to grow the cells. The cells are grown until they are 50 to 80% confluent.

Any method for making a cell extract may be used, for example, by lysis with a detergent such as Nonidet P-40 (NP-40), Triton-X-100, and the like, in a suitable buffer. Preferably, a lysis buffer containing 0.1% NP-40, 100 mM trishydroxymethylaminomethane pH 7.4, and 120 mM NaCl is used. Alternatively a cell lysate may be obtained by other methods well known in the art, for example, using sonication, osmotic shock, or mechanical rupture. Nuclear extracts prepared according to standard procedures may also be used to prepare cyclin/cyclin-dependent kinase complexes for use in the method of the invention. Protease inhibitors such as phenylmethylsulfonyl fluoride, aprotinin, leupeptin, and the like are included in the lysis buffer prior to further processing. After lysis, the lysate is centrifuged to remove cellular debris and the supernatant containing the cyclin/cyclin dependent kinase complexes is retained. This supernatant may be quick frozen and stored at ultralow temperatures (i.e., at about -80.degree. C.) prior to use, or it may be subjected to further processing without freezing.

Cyclin/cyclin dependent kinase complexes are isolated from the supernatant using any suitable method, for example immunoprecipitation, affinity chromatography, preparative gel electrophoresis, and the like. Alternatively, the cyclin/cyclin dependent kinase complexes may be in the form of reconstituted complexes derived from recombinant expression of the DNA sequences encoding the respective proteins. Methods for expressing DNA sequences to obtain recombinant proteins are generally described below. Methods for co-expressing proteins are known. Preferably the cyclin/cyclin dependent kinase complexes are isolated using immunoprecipitation. More preferably, the cyclin/cyclin dependent kinase complexes are immunoprecipitated using a monoclonal antibody specific for a cyclin or for its specifically associated cyclin dependent kinase. Cyclin/cyclin dependent kinase complexes isolated in this way are precipitated using a secondary reagent such as protein A, protein G, sepharose-conjugated protein A or protein G, or a suitable second antibody. Most preferably, a monoclonal antibody specific for a cyclin or for its specifically associated cyclin dependent kinase, which is conjugated to a carrier resin such as agarose or sepharose, is used to immunoprecipitate the cyclin/cyclin dependent kinase complexes used in the method of the invention. Monoclonal antibodies specific for cyclins are known and are commercially available: for example, a monoclonal antibody specific for cyclin A which is conjugated to agarose beads is available from Santa Cruz Biotechnology (catalog number sc-239 AC). Commercially available monoclonal antibodies specific for other cyclins or cyclin-dependent kinases are identified in Linscott's Directory of Immunological & Biological Reagents (4877 Grange Road, Santa Rosa, Calif. 95404). Alternatively, purified cyclins or cyclin-dependent kinases may act as immunogens to produce monoclonal antibodies using known methods, such as those described in Antibodies, A Laboratory Manual, E. Harlow and D. Lane, Cold Spring Harbor Laboratory Press (1988).

The isolated cyclin/cyclin-dependent kinase complexes are washed to remove substances which could produce artifacts. Any suitable buffer which maintains the conformation of the cyclin/cyclin-dependent kinase complex may be used to perform this washing. Preferably, the lysis buffer described above is used to wash the complexes. A buffer suitable for performance of kinase assays is then used to wash the cyclin/cyclin-dependent kinase complexes further, thereby equilibrating the complexes for the remaining steps of the method. Any buffer suitable for performing kinase assays may be used for this washing/equilibration step. Preferably, a buffer comprised of 50 mM trishydroxymethylaminomethane, pH 7.4, and 20 mM MgCl.sub.2 is used to wash and equilibrate the cyclin/cyclin-dependent kinase complexes.

After the isolated cyclin/cyclin-dependent kinase complexes are washed and equilibrated, they are resuspended in a kinase buffer and aliquotted. Preferably, the kinase buffer contains 50 mM trishydroxymethylaminomethane, pH 7.4, 20 mM MgCl.sub.2, 1 mM dithiothreitol, and, optionally, 100 .mu.M unlabeled adenosine triphosphate. The CDI and HPV E7 proteins are then added to each aliquot and allowed to interact on ice for a suitable time, preferably about ten minutes. Appropriate controls are performed in parallel aliquots. A dephosphorylated phosphoprotein and a compound capable of donating a labeled molecule to a phosphate accepting site on the phosphoprotein are then added to each aliquot, and a kinase reaction is allowed to proceed at a suitable temperature and for a suitable time, both of which may be determined using known methods of chemical kinetics analysis. The kinase reaction is quenched using a buffer containing a suitable quenching agent such as sodium dodecyl sulfate, and the relative amounts of phosphorylated phosphoprotein are measured and compared.

Any form of the CDI protein may be used in the methods of the invention, so long as the CDI protein maintains its ability to inhibit the kinase activity and to interact with an HPV E7 oncoprotein. For example, the CDI protein may be in the form of a recombinantly expressed protein, which may optionally be fused to a carrier molecule such as glutathione-S-transferase. Fragments of the CDI protein which retain the ability to interact with and inactivate cyclin/cyclin-dependent kinase complexes may also be employed in the method of the invention.

Similarly, any form of HPV E7 oncoprotein may be used in the methods of the invention, so long as the HPV E7 oncoprotein maintains its ability to interact with and/or inactivate the cyclin/cyclin-dependent kinase inhibitor protein used in the method. For example, the HPV-16 E7 oncoprotein having the amino acid sequence set forth in SEQ ID NO:5 and SEQ ID NO:6 may be used in the methods of the invention, or fragments of the HPV E7 oncoprotein which retain the ability to interact with and/or inactivate the cyclin/cyclin-dependent kinase inhibitor protein used in the method may be employed in the method of the invention. The HPV E7 oncoprotein may be used in the form of a recombinantly expressed protein, which may optionally be fused to a carrier molecule such as glutathione-S-transferase.

When the proteins used in the methods of the invention are recombinantly expressed, DNAs encoding the proteins such as those set forth in SEQ ID NO:1, SEQ ID NO:3, and SEQ ID NO:5 are operably linked to an expression control sequence. As defined herein, "operably linked" means enzymatically or chemically ligated to form a covalent bond between the DNA encoding the protein and the expression control sequence, said ligation being effected in such a way that the protein is expressed by a host cell which has been transformed (transfected) with the ligated DNA/expression control sequence. Many suitable expression control sequences are known in the art, for example, general methods of expressing recombinant proteins in mammalian cells are also known and are exemplified in R. Kaufman, Methods in Enzymology 185, 537-566 (1990). Many DNA vectors for expression of proteins in mammalian cells are known, for example, the pcDNA3 or the pRc/RSV vectors available from Invitrogen, San Diego, Calif. U.S.A.

A number of types of mammalian cells may act as suitable host cells for expression of the proteins used in the methods of the invention. For example, suitable mammalian host cells include, monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney 293 cells, human epidermal A431 cells, human Colo205 cells, mouse 3T3 cells, CV-1 cells, other transformed primate cell lines, HeLa cells, mouse L cells, baby hamster kidney (BHK) cells, HL-60 cells, U937 cells, hamster kidney (HaK) cells, or the like.

Alternatively, the proteins used in the methods of the invention may be recombinantly produced by operably linking the DNAs which encode them to suitable control sequences in one or more insect expression vectors, and employing an insect expression system. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, e.g., Invitrogen, San Diego, Calif. U.S.A. (the MacBac.RTM. kit) or PharMingen, San Diego, Calif. U.S.A. (the BaculoGold.TM. Transfection Kit). Such methods are well known in the art, as described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987), incorporated herein by reference.

The proteins used in the present invention may also be produced in lower eukaryotes such as yeast or in prokaryotes such as bacteria. When expressed in yeast, the DNAs encoding the proteins used in the methods of the invention are operably linked to an expression control sequence suitable for expression in yeast. Many vectors for expression of heterologous proteins in yeast are known, for example, the pYES2 vector available from Invitrogen, San Diego, Calif. U.S.A. Potentially suitable yeast host cell strains include Saccharomyces cerevisiae, Schizosaccharomyces pombe, Kluyveromyces strains, Candida, or any yeast strain capable of expressing heterologous proteins. When expressed in bacteria, the DNAs encoding the proteins used in the methods of the invention are operably linked to an expression control sequence suitable for expression in bacteria. Many vectors for expression of heterologous proteins in bacteria are known. Potentially suitable bacterial host cells include Escherichia coli, Bacillus subtilis, attenuated strains of Salmonella typhimurium, and the like. When expressed in bacteria, the proteins used in the method of the invention may be initially obtained in inclusion bodies and may be refolded using known methods and chaotropic agents. Bacterially expressed proteins for use in the invention may also be obtained in the form of fusion proteins, for example, as glutathione-S-transferase or .beta.-galactosidase fusion proteins, using methods which are well known in the art, for example, using the pGEX vectors available from Pharmacia, Piscataway, N.J., U.S.A.

Any dephosphorylated phosphoprotein may be used to measure the kinase activity of the cyclin/cyclin dependent kinase complexes in accordance with the method of the invention. For example, dephosphorylated histories may be used as substrates for the cyclin/cyclin dependent kinase complexes, in performing the method of the invention. Casein (e.g., cat. #c-4032, Sigma, St. Louis, Mo. U.S.A.) may also be used as a substrate for the cyclin/cyclin dependent kinase complexes in accordance with the invention. Preferably, historic H1 is used to perform the method of the invention. Historic H1 suitable for use in the method of the invention is commercially available from Boehringer-Mannheim, Indianapolis, Ind., U.S.A. (cat. #223-549).

Any compound capable of donating a labeled molecule to a phosphate accepting site on the phosphoprotein and that can serve as a substrate for the kinase may be used to perform the kinase assay used in the method of the invention. For example, a labeled phosphate compound or a labeled phosphate analog compound may be used in the kinase assay in accordance with the present invention. Preferably, a labeled nucleoside triphosphate, in particular, a labeled adenosine triphosphate may be used to donate the labeled phosphate to the dephosphorylated phosphoprotein. Alternatively a labeled nucleoside triphosphate analog such as a labeled nucleoside phosphorothioate may be used to donate a labeled sulfate to the dephosphorylated phosphoprotein. The label on the phosphate or phosphate analog compound will preferably occur at the .gamma.-position of the phosphate or phosphorothioate moiety of the donating compound. Any kind of label may be used to perform the method of the invention. Preferably, a chemiluminescent label is used to label the .gamma.-position of the phosphate or phosphorothioate moiety of the donating compound. More preferably, a radioactive label is used to label the .gamma.-position of the phosphate or phosphorothioate moiety of the donating compound. Any radioactive label may be used, however, .sup.32 p, .sup.33 p, or .sup.35 S are preferable as labels in the .gamma.-position of the phosphate or phosphorothioate moiety of the donating compound.

When the method of the invention is used to identify a compound that inhibits the ability of HPV E7 oncoprotein to stimulate proliferation of a population of infected cells, mammalian cells infected with HPV are used to prepare the cyclin/cyclin-dependent kinase complexes. Alternatively, mammalian cells containing the HPV E6 and/or E7 oncogenes are used to prepare the cyclin/cyclin-dependent kinase complexes. Any HPV-infected mammalian cell may be used in this embodiment of the invention, for example, any of the mammalian cells identified above may be used. Preferably, a transformed cell line derived from a cervical or penile carcinoma is used to perform this embodiment of the method of the invention. Many such cell lines are known, for example, HeLa cells, SiHa, CaSki, C4-I, and the like.

In accordance with this embodiment, a test compound is added to at least one aliquot of the isolated cyclin/cyclin-dependent kinase complexes in kinase buffer. Of course, a plurality of test compounds may be tested at one time using multiwell microtiter plates or any other apparatus suitable for assaying multiple samples. The method of identifying a compound that inhibits the ability of HPV E7 oncoprotein to stimulate proliferation of a population of infected cells may be robotized in accordance with the present invention.

The kinase activities of the cyclin/cyclin-dependent kinase complexes in the presence of the test compound are measured and compared to those of control aliquots which do not contain the test compound. In accordance with the invention, a test compound having a kinase activity which is less than that of the control aliquot is considered to be capable of inhibiting the ability of HPV oncoprotein E7 to stimulate proliferation of the HPV-infected cell. Compounds found to reduce the control aliqout's kinase activity by at least 10%, preferably greater than about 50% or more of the control aliquot's kinase activity may thus be identified and then secondarily screened in other proliferation assays, including growth suppression in HPV-positive cells such as HeLa cells, CaSki cells, SiHa cells, C4-I cells, and the like. By these means compounds having inhibitory activity for HPV oncoprotein E7-mediated stimulation of proliferation of HPV-infected cells may be identified.

The present invention is also embodied as a kit for determining or diagnosing the proliferative state of a population of cells infected with a human papillomavirus or for determining or diagnosing the proliferative state of a population of transformed cells. The kit for determining or diagnosing the proliferative state of a population of cells infected with a human papillomavirus comprises a CDI protein, a dephosphorylated phosphoprotein, and a compound capable of donating a labeled molecule to a phosphate accepting site on the dephosphorylated phosphoprotein, said compound being selected from the group consisting of a labeled phosphate and a labeled phosphate analog. Any form of the CDI protein may be included in the kit of the invention, so long as the CDI protein maintains its ability to inhibit the kinase activity and to interact with and/or to be inactivated by an HPV E7 oncoprotein. For example, the CDI protein may be in the form of a recombinantly expressed protein, which may optionally be fused to a carrier molecule such as glutathione-S-transferase or .beta.-galactosidase. Fragments of the CDI protein which retain the ability to interact with and/or inactivate cyclin/cyclin-dependent kinase complexes may also be included in the kit of the invention.

The kit for determining or diagnosing the proliferative state of a population of transformed cells comprises an HPV E7 oncoprotein, a dephosphorylated phosphoprotein, and a compound capable of donating a labeled molecule to a phosphate accepting site on the dephosphorylated phosphoprotein, said compound being selected from the group consisting of a labeled phosphate and a labeled phosphate analog. Any form of the HPV E7 oncoprotein may be included in the kit of the invention, so long as the HPV E7 ontoprotein maintains its ability to inhibit the kinase activity and/or to interact with a CDI within the transformed cell. For example, the HPV E7 oncoprotein may be in the form of a recombinantly expressed protein, which may optionally be fused to a carrier molecule such as glutathione-S-transferase or .beta.-galactosidase. Fragments of the HPV E7 oncoprotein which retain the ability to interact with and/or activate cyclindcyclin-dependent kinase complexes may also be included in the kit of the invention.

Any dephosphorylated phosphoprotein may be included in the kit of the invention. Preferably, a histone or casein is included in the kit of the invention. Histone H 1 is especially preferred for inclusion in the kit of the invention. Any compound capable of donating a labeled molecule to a phosphate accepting site on the phosphoprotein may be included in the kit of the invention. For example, a labeled phosphate compound or a labeled phosphate analog compound may be included in the kit of the present invention. Preferably, a labeled nucleoside triphosphate, in particular, a labeled adenosine triphosphate may be included in the kit of the invention to donate the labeled phosphate to the dephosphorylated phosphoprotein. Alternatively a labeled nucleoside triphosphate analog such as a labeled nucleoside phosphorothioate may be included in the kit. The label on the phosphate or phosphate analog compound will preferably occur at the .gamma.-position of the phosphate or phosphorothioate moiety of the donating compound. Any kind of label may be included in the kit of the invention. Preferably, a chemiluminescent label is used to label the .gamma.-position of the phosphate or phosphorothioate moiety of the donating compound. More preferably, a radioactive label is used to label the .gamma.-position of the phosphate or phosphorothioate moiety of the donating compound. Any radioactive label may be used, however, .sup.32 p, .sup.33 p, or .sup.35 S are preferable as labels in the .gamma.-position of the phosphate or phosphorothioate moiety of the donating compound.

The invention as embodied in a diagnostic method for evaluating the proliferative state of a transformed cell may be performed on any transformed cell which contains a CDI capable of interacting with and/or capable of being inactivated by an HPV E7 oncoprotein. The diagnostic method is preferably performed on biopsied tissue which includes both transformed and untransformed cells, so that control cells are available which are substantially homogeneic with the transformed cell. In accordance with the invention, "substantially homogeneic" is defined as being derived from the same organism. The transformed and untransformed cells are separated from each other using known methods, such as Ficoll gradient separation or fluorescence-activated cell sorting. An extract or lysate may be made of the transformed cell, and a parallel extract or lysate is made of the untransformed cell. Cyclin/cyclin-dependent kinase complexes are isolated from the lysates as described above, and aliquotted. Aliquots of the transformed and untransformed cell cyclin/cyclin-dependent kinase complexes are incubated with an I-IPV E7 oncoprotein, and appropriate controls are included. The kinase activities of the cyclin/cyclin-dependent kinase complexes in the presence of the HPV E7 oncoprotein are measured as described above and compared to those of control aliquots which do not contain the HPV E7 oncoprotein. In accordance with the present invention, the kinase activity of a proliferating transformed cell will be substantially greater than that of the substantially homogeneic untransformed cell.

Alternatively the biopsy tissue containing the transformed and untransformed cells are fixed as for immunohistochemical staining using known methods. The fixed tissue is serially sectioned using known methods. Cyclin/cyclin-dependent kinase complexes are detected using polyclonal antibodies specific for a cyclin or for its specifically associated cyclin dependent kinase, or preferably using one or more monoclonal antibodies specific for a cyclin or for its specifically associated cyclin dependent kinase. An HPV E7 oncoprotein is added to the fixed tissues, and allowed to interact with the CDIs in the fixed tissues. Unbound E7 is removed from the fixed tissue, and the interaction between the CDI present in the fixed tissue and HPV E7 oncoprotein is measured, for example, using an antibody specific for HPV E7 oncoprotein.

The invention is also embodied as a method of inhibiting growth of an HPV-infected cell or hyperplastic lesion comprising administering to the cell a therapeutically effective amount of a compound that interferes with the ability of HPV oncoprotein E7 to interact with a CDI. As used herein, an "HPV-infected cell" is defined as a cell containing one or more DNA sequences characteristic of an HPV strain, including a DNA sequence encoding the E7 oncoprotein. As used herein, a "hyperplastic lesion" is defined as being composed of one or more cells containing one or more DNA sequences characteristic of a high-risk HPV strain, including a DNA sequence encoding the E7 oncoprotein. Further as defined herein, the term "therapeutically effective amount" means the total amount of the compound that is sufficient to show a meaningful amount of growth inhibition for the HPV-infected cell. When the HPV-infected cell is contained within a tumor, the term "therapeutically effective amount" additionally means the total amount of each active component of a pharmaceutical composition containing the compound to show any amount of inhibition of tumor growth.

In practicing the invention's method of inhibiting growth of an HPV-infected cell, a therapeutically effective amount of the compound that interferes with the ability of HPV oncoprotein E7 to interact with and/or inactivate a CDI (hereinafter "the inhibitory compound") is administered to a cell or to a lesion within a mammal, said lesion containing HPV genes or HPV antigens, including the E7 oncoprotein. The inhibitory compound may be administered either alone or in combination with other therapies such as chemotherapeutic agents, radiation therapy, or in combination with treatments employing one or more cytokines, lymphokines, or other hematopoietic factors. When co-administered with one or more cytokines, lymphokines, or other hematopoietic factors, the inhibitory compound may be administered either simultaneously with the cytokines, lymphokines, or other hematopoietic factors, or sequentially. If administered sequentially, the attending physician will determine the appropriate sequence of administering the inhibitory compound in combination with cytokines, lymphokines, or other hematopoietic factors.

Administration of the inhibitory compound in accordance with the method of the present invention can be carried out in a variety of conventional ways, such as oral ingestion, inhalation, or cutaneous, subcutaneous, or intravenous injection.

When a therapeutically effective amount of the inhibitory compound is administered orally, the compound will be in the form of a tablet, capsule, powder, solution or elixir. When administered in tablet form, the pharmaceutical composition used in this embodiment of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant. The tablet, capsule, and powder contain from about 5 to 95% of the inhibitory compound and preferably from about 25 to 90% of the inhibitory compound. When administered in liquid form, a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, sesame oil, or synthetic oils may be added. The liquid form of the pharmaceutical composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol. When administered in liquid form, the pharmaceutical composition contains from about 0.5 to 90% by weight of the inhibitory compound and preferably from about 1 to 50% of the inhibitory compound.

When a therapeutically effective amount of the inhibitory compound is administered by intravenous, cutaneous or subcutaneous injection, the inhibitory compound will be in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such parenterally acceptable solutions, having due regard to pH, isotonicity, stability, and the like, is within the skill in the art. A preferred pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to the inhibitory compound, an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the art. The pharmaceutical composition used in the therapeutic method of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art.

The amount of inhibitory compound in the pharmaceutical composition used in the therapeutic method of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone. Ultimately, the attending physician will decide the amount of inhibitory compound with which to treat each individual patient. Initially, the attending physician will administer low doses of the inhibitory compound and observe the patient's response. Larger doses of inhibitory compound may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not increased further. It is contemplated that the various pharmaceutical compositions used to practice the method of the present invention should contain about 0.1 .mu.g to about 100 mg of inhibitory compound per kg body weight.

The duration of intravenous therapy in accordance with the present invention will vary, depending on the severity of the disease being treated and the condition and potential idiosyncratic response of each individual patient. It is contemplated that the duration of each application of the inhibitory compound will be in the range of 12 to 24 hours of continuous intravenous administration. Ultimately the attending physician will decide on the appropriate duration of intravenous therapy with an inhibitory compound in accordance with the present invention.

Those of skill in the art will recognize that the invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The presently described embodiments are therefore to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description, and all variations of the invention which are encompassed within the meaning and range of equivalency of the claims are therefor intended to be embraced therein. SEQUENCE LISTING (1) GENERAL INFORMATION: (iii) NUMBER OF SEQUENCES: 6 (2) INFORMATION FOR SEQ ID NO:1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 495 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (B) STRAIN: WI38 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..495 (x) PUBLICATION INFORMATION: (A) AUTHORS: Xiong, Y. Hannon, G. J. Zhang, H. Casso, D. Kobayashi, R. Beach, D. (B) TITLE: p21 is a Universal Inhibitor of Cyclin Kinase (C) JOURNAL: Nature (D) VOLUME: 366 (E) ISSUE: 6456 (F) PAGES: 701-704 (G) DATE: 1993 (K) RELEVANT RESIDUES IN SEQ ID NO:1: FROM 1 TO 495 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1: ATGTCAGAACCGGCTGGGGATGTCCGTCAGAACCCATGCGGCAGCAAG48 MetSerGluProAlaGlyAspValArgGlnAsnProCysGlySerLys 151015 GCCTGCCGCCGCCTCTTCGGCCCAGTGGACAGCGAGCAGCTGAGCCGC96 AlaCysArgArgLeuPheGlyProValAspSerGluGlnLeuSerArg 202530 GACTGTGATGCGCTAATGGCGGGCTGCATCCAGGAGGCCCGTGAGCGA144 AspCysAspAlaLeuMetAlaGlyCysIleGlnGluAlaArgGluArg 354045 TGGAACTTCGACTTTGTCACCGAGACACCACTGGAGGGTGACTTCGCC192 TrpAsnPheAspPheValThrGluThrProLeuGluGlyAspPheAla 505560 TGGGAGCGTGTGCGGGGCCTTGGCCTGCCCAAGCTCTACCTTCCCACG240 TrpGluArgValArgGlyLeuGlyLeuProLysLeuTyrLeuProThr 65707580 GGGCCCCGGCGAGGCCGGGATGAGTTGGGAGGAGGCAGGCGGCCTGGC288 GlyProArgArgGlyArgAspGluLeuGlyGlyGlyArgArgProGly 859095 ACCTCACCTGCTCTGCTGCAGGGGACAGCAGAGGAAGACCATGTGGAC336 ThrSerProAlaLeuLeuGlnGlyThrAlaGluGluAspHisValAsp 100105110 CTGTCACTGTCTTGTACCCTTGTGCCTCGCTCAGGGGAGCAGGCTGAA384 LeuSerLeuSerCysThrLeuValProArgSerGlyGluGlnAlaGlu 115120125 GGGTCCCCAGGTGGACCTGGAGACTCTCAGGGTCGAAAACGGCGGCAG432 GlySerProGlyGlyProGlyAspSerGlnGlyArgLysArgArgGln 130135140 ACCAGCATGACAGATTTCTACCACTCCAAACGCCGGCTGATCTTCTCC480 ThrSerMetThrAspPheTyrHisSerLysArgArgLeuIlePheSer 145150155160 AAGAGGAAGCCCTAA495 LysArgLysPro 165 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 164 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: MetSerGluProAlaGlyAspValArgGlnAsnProCysGlySerLys 151015 AlaCysArgArgLeuPheGlyProValAspSerGluGlnLeuSerArg 202530 AspCysAspAlaLeuMetAlaGlyCysIleGlnGluAlaArgGluArg 354045 TrpAsnPheAspPheValThrGluThrProLeuGluGlyAspPheAla 505560 TrpGluArgValArgGlyLeuGlyLeuProLysLeuTyrLeuProThr 65707580 GlyProArgArgGlyArgAspGluLeuGlyGlyGlyArgArgProGly 859095 ThrSerProAlaLeuLeuGlnGlyThrAlaGluGluAspHisValAsp 100105110 LeuSerLeuSerCysThrLeuValProArgSerGlyGluGlnAlaGlu 115120125 GlySerProGlyGlyProGlyAspSerGlnGlyArgLysArgArgGln 130135140 ThrSerMetThrAspPheTyrHisSerLysArgArgLeuIlePheSer 145150155160 LysArgLysPro (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 597 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (D) DEVELOPMENTAL STAGE: Adult (F) TISSUE TYPE: Kidney (vii) IMMEDIATE SOURCE: (B) CLONE: p27kip1 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..597 (x) PUBLICATION INFORMATION: (A) AUTHORS: Polyak, K. Lee, Mong- Hong Erdjument- Breomage, H. Koff, A. Roberts, J. M. Tempst, P. Massague, J. (B) TITLE: Cloning of p27kip1, a Cyclin-dependent Kinase Inhibitor, and a Potential Mediator of Extracellular Antimitogenic Signals (C) JOURNAL: Cell (D) VOLUME: 78 (F) PAGES: 56-66 (G) DATE: 1994 (K) RELEVANT RESIDUES IN SEQ ID NO:3: FROM 1 TO 597 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: ATGTCAAACGTGCGAGTGTCTAACGGGAGCCCTAGCCTGGAGCGGATG48 MetSerAsnValArgValSerAsnGlySerProSerLeuGluArgMet 151015 GACGCCAGGCAGGCGGAGCACCCCAAGCCCTCGGCCTGCAGGAACCTC96 AspAlaArgGlnAlaGluHisProLysProSerAlaCysArgAsnLeu 202530 TTCGGCCCGGTGGACCACGAAGAGTTAACCCGGGACTTGGAGAAGCAC144 PheGlyProValAspHisGluGluLeuThrArgAspLeuGluLysHis 354045 TGCAGAGACATGGAAGAGGCGAGCCAGCGCAAGTGGAATTTCGATTTT192 CysArgAspMetGluGluAlaSerGlnArgLysTrpAsnPheAspPhe 505560 CAGAATCACAAACCCCTAGAGGGCAAGTACGAGTGGCAAGAGGTGGAG240 GlnAsnHisLysProLeuGluGlyLysTyrGluTrpGlnGluValGlu 65707580 AAGGGCAGCTTGCCCGAGTTCTACTACAGACCCCCGCGGCCCCCCAAA288 LysGlySerLeuProGluPheTyrTyrArgProProArgProProLys 859095 GGTGCCTGCAAGGTGCCGGCGCAGGAGAGCCAGGATGTCAGCGGGAGC336 GlyAlaCysLysValProAlaGlnGluSerGlnAspValSerGlySer 100105110 CGCCCGGCGGCGCCTTTAATTGGGGCTCCGGCTAACTCTGAGGACACG384 ArgProAlaAlaProLeuIleGlyAlaProAlaAsnSerGluAspThr 115120125 CATTTGGTGGACCCAAAGACTGATCCGTCGGACAGCCAGACGGGGTTA432 HisLeuValAspProLysThrAspProSerAspSerGlnThrGlyLeu 130135140 GCGGAGCAATGCGCAGGAATAAGGAAGCGACCTGCAACCGACGATTCT480 AlaGluGlnCysAlaGlyIleArgLysArgProAlaThrAspAspSer 145150155160 TCTACTCAAAACAAAAGAGCCAACAGAACAGAAGAAAATGTTTCAGAC528 SerThrGlnAsnLysArgAlaAsnArgThrGluGluAsnValSerAsp 165170175 GGTTCCCCAAATGCCGGTTCTGTGGAGCAGACGCCCAAGAAGCCTGGC576 GlySerProAsnAlaGlySerValGluGlnThrProLysLysProGly 180185190 CTCAGAAGACGTCAAACGTAA597 LeuArgArgArgGlnThr 195 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 198 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: MetSerAsnValArgValSerAsnGlySerProSerLeuGluArgMet 151015 AspAlaArgGlnAlaGluHisProLysProSerAlaCysArgAsnLeu 202530 PheGlyProValAspHisGluGluLeuThrArgAspLeuGluLysHis 354045 CysArgAspMetGluGluAlaSerGlnArgLysTrpAsnPheAspPhe 505560 GlnAsnHisLysProLeuGluGlyLysTyrGluTrpGlnGluValGlu 65707580 LysGlySerLeuProGluPheTyrTyrArgProProArgProProLys 859095 GlyAlaCysLysValProAlaGlnGluSerGlnAspValSerGlySer 100105110 ArgProAlaAlaProLeuIleGlyAlaProAlaAsnSerGluAspThr 115120125 HisLeuValAspProLysThrAspProSerAspSerGlnThrGlyLeu 130135140 AlaGluGlnCysAlaGlyIleArgLysArgProAlaThrAspAspSer 145150155160 SerThrGlnAsnLysArgAlaAsnArgThrGluGluAsnValSerAsp 165170175 GlySerProAsnAlaGlySerValGluGlnThrProLysLysProGly 180185190 LeuArgArgArgGlnThr 195 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 297 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (vi) ORIGINAL SOURCE: (A) ORGANISM: Human papillomavirus (B) STRAIN: HPV-16 (vii) IMMEDIATE SOURCE: (B) CLONE: E7 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..297 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: ATGCATGGAGATACACCTACATTGCATGAATATATGTTAGATTTGCAA48 MetHisGlyAspThrProThrLeuHisGluTyrMetLeuAspLeuGln 151015 CCAGAGACAACTGATCTCTACTGTTATGAGCAATTAAATGACAGCTCA96 ProGluThrThrAspLeuTyrCysTyrGluGlnLeuAsnAspSerSer 202530 GAGGAGGAGGATGAAATAGATGGTCCAGCTGGACAAGCAGAACCGGAC144 GluGluGluAspGluIleAspGlyProAlaGlyGlnAlaGluProAsp 354045 AGAGCCCATTACAATATTGTAACCTTTTGTTGCAAGTGTGACTCTACG192 ArgAlaHisTyrAsnIleValThrPheCysCysLysCysAspSerThr 505560 CTTCGGTTGTGCGTACAAAGCACACACGTAGACATTCGTACTTTGGAA240 LeuArgLeuCysValGlnSerThrHisValAspIleArgThrLeuGlu 65707580 GACCTGTTAATGGGCACACTAGGAATTGTGTGCCCCATCTGTTCTCAG288 AspLeuLeuMetGlyThrLeuGlyIleValCysProIleCysSerGln 859095 AAACCATAA297 LysPro (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 98 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: MetHisGlyAspThrProThrLeuHisGluTyrMetLeuAspLeuGln 151015 ProGluThrThrAspLeuTyrCysTyrGluGlnLeuAsnAspSerSer 202530 GluGluGluAspGluIleAspGlyProAlaGlyGlnAlaGluProAsp 354045 ArgAlaHisTyrAsnIleValThrPheCysCysLysCysAspSerThr 505560 LeuArgLeuCysValGlnSerThrHisValAspIleArgThrLeuGlu 65707580 AspLeuLeuMetGlyThrLeuGlyIleValCysProIleCysSerGln 859095 LysPro __________________________________________________________________________

## Claims

1. A method of evaluating the proliferative state of a human papillomavirus transformed cell which comprises: p21.sup.CIP1 protein from the cell, and dividing said complexes into a plurality of aliquots; step a, wherein E7 oncoprotein interacts with the p21.sup.CIP1 protein in the complexes of step a; the transformed cell; untransformed cell of step c, and dividing said complexes into a plurality of aliquots; step d, wherein E7 oncoprotein interacts with the p21.sup.CIP1 protein in the complexes of step d; and wherein a proliferating transformed cell is characterized by a greater kinase activity in comparison to the kinase activity of the substantially homogeneic untransformed cell.